GleamWall
中文EN

ENGN enGene Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1980845 · Fiscal year ends 10/31

Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.6%
TTM EPS YoY305.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-60.5%
ROA-48.8%
ROIC (approx.)-60.4%
Asset turnover—

Leverage & solvency

Liabilities / assets20.1%
Debt / equity0.00x
Current ratio10.21x
Interest coverage-44.51x

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-07-312026Q22026-04-302026Q12026-01-312025Q4*2025-10-312025Q32025-07-312025Q22025-04-302025Q12025-01-312024Q4*2024-10-31
Income statement
Revenue————————
R&D expense$20.09M$22.20M$22.25M$31.72M$22.57M$20.21M$19.97M$11.27M
SG&A expense$13.92M$9.77M$8.93M$7.76M$7.37M$6.92M$6.64M$6.18M
Operating income-$34.01M-$31.97M-$31.18M-$39.48M-$29.95M-$27.12M-$26.61M-$17.45M
Interest expense$843,000$745,000$732,000$750,000$758,000$734,000$752,000$756,000
Pretax income-$32.50M-$30.23M-$29.75M-$38.38M-$28.75M-$25.57M-$24.60M-$15.28M
Income tax$0$0$0-$497,000$239,000$240,000$18,000$19,000
Net income-$32.50M-$30.23M-$29.75M-$37.88M-$28.99M-$25.82M-$24.62M-$15.30M
EBITDA-$33.91M-$31.77M-$31.00M-$39.28M-$29.85M-$27.02M-$26.51M-$17.36M
EPS (basic)-0.47-0.430.44—-0.57-0.510.48—
EPS (diluted)-0.47-0.430.44—-0.57-0.510.48—
Dividends declared per share0.000.000.000.000.000.000.000.00
Weighted avg. shares (diluted)69.73M69.72M67.26M—51.10M51.02M50.98M—
Balance sheet
Cash & equivalents$41.02M$29.83M$36.61M$50.15M$32.62M$57.55M$62.35M$173.00M
Short-term investments$225.29M$228.64M$239.34M$143.58M$169.29M$159.85M$151.47M$65.33M
Current assets$277.90M$270.00M$289.22M$201.39M$211.31M$227.97M$222.32M$247.36M
PP&E, net$2.16M$2.33M$2.44M$2.48M$1.88M$1.55M$1.37M$1.17M
Total assets$288.32M$307.52M$337.11M$221.47M$245.55M$266.65M$285.93M$311.17M
Current liabilities$27.21M$21.48M$24.61M$31.98M$20.44M$18.00M$12.96M$14.66M
Total liabilities$58.03M$52.36M$55.57M$53.76M$44.88M$39.36M$35.98M$38.56M
Shareholders' equity$230.29M$255.17M$281.55M$167.71M$200.67M$227.29M$249.95M$272.61M
Shares outstanding67.01M66.99M66.99M52.02M51.11M51.07M50.98M50.98M
Cash flow statement
Operating cash flow-$18.95M-$30.50M-$28.90M-$24.96M-$25.63M-$22.95M-$25.70M-$19.57M
Capital expenditure$0$98,000$153,000$437,000$704,000$45,000$299,000$238,000
Free cash flow-$18.95M-$30.60M-$29.06M-$25.40M-$26.34M-$22.99M-$26.00M-$19.81M
Investing cash flow$30.12M$23.64M-$126.30M$40.50M$1.38M$17.95M-$84.96M-$125.27M
Financing cash flow$23,000$74,000$141.66M$1.99M-$667,000$199,000$1,000$60.16M
Depreciation & amortization$100,000$200,000$189,000$200,000$100,000$100,000$102,000$100,000
Stock-based compensation$7.81M$4.14M$2.80M$2.61M$2.58M$2.65M$1.81M$1.66M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.